Elyxyb Alternatives Compared
Elyxyb | Galcanezumab | Atogepant |
|
---|
Elyxyb (celecoxib) | Galcanezumab | Atogepant |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Migraine. Elyxyb may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cluster Headaches, Migraine Prevention, Chronic Migraine, Headache, Migraine. galcanezumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Chronic Migraine, Migraine Prevention, Headache, Migraine. atogepant may also be used for purposes not listed in this medication guide. |
Related suggestions Migraine
|
|||||||
More about Elyxyb (celecoxib) | More about Galcanezumab | More about Atogepant | ||||||||
Ratings & Reviews | ||||||||||
Be the first to share your experience with this drug. |
Galcanezumab has an average rating of 5.1 out of 10 from a total of 475 ratings on Drugs.com. 36% of reviewers reported a positive effect, while 46% reported a negative effect. |
Atogepant has an average rating of 7.9 out of 10 from a total of 142 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 9% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
See also: Elyxyb side effects in more detail. |
See also: galcanezumab side effects in more detail. |
See also: atogepant side effects in more detail. |
||||||||
Generic Availability | ||||||||||
N/A |
N/A |
|||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
View all Elyxyb prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Dosage Forms Available | ||||||||||
|
N/A |
N/A |
||||||||
Brand Names | ||||||||||
Other celecoxib brands include: Celebrex | Emgality | Qulipta | ||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
11 hours |
648 hours |
11 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Category C
Risk cannot be ruled out
Prior To 30 Weeks Gestation
Category D
Positive evidence of risk
Starting At 30 Weeks Gestation See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 419 drugs are known to interact with Elyxyb:
|
A total of 2 drugs are known to interact with galcanezumab:
|
A total of 181 drugs are known to interact with atogepant:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | ||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||
First Approval Date | ||||||||||
May 05, 2020 |
N/A |
September 28, 2021 |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.